BioServices Benten, Inc. , ( BentenBio’s Com), a privately-held contract services organization headquartered in Malvern, PA, today announced the completion of $1 last month. $1 million in new convertible debt financing Benten raised $2 in August 94 million in Series A Preferred Stock funding, bringing the total amount Benten raised to $4 in 2012. $0 million Investments in the Series A round included the Life Sciences Greenhouse of Central Pennsylvania (LSGPA), Penn Venture Partners, and private qualified investors led by Capgenic Advisors.
The company’s core business focuses on testing and optimizing regulated biologics, the fastest growing segment of the pharmaceutical market. In line with the company’s goal of becoming the market leader in this niche, Benten developed a robust range of services and hired a strong, experienced commercial team after the construction of its 35.000 square-foot, state-of-the-art cGMP facility at the end of Q1.
“We are pleased with the continued confidence our investors have shown in the Company,” said Paula MacDonald, President and CEO of Benten. Thomas A’s Penn, Partner at Penn Venture Partners, said, “The Benten team has been very successful in this contract services ecosystem before, and we have great confidence in their ability to grow this business in an expanding marketplace. “That’s right.
BioServices Benten, Inc. , is a contract services organization (CSO) focused on biological safety testing and biomanufacturing services for the biotechnological and pharmaceutical industries. By leveraging the diverse experience of its team, the Company offers a different kind of CSO experience, one that offers a more advanced service model to provide its clients with regulatory solutions that are flexible and of high quality. For more information on Benten BioServices, please visit
